THIS MONTH’S ISSUE

Read, save, and print articles from the current issue

ARTICLES

Chronological index
2013–2018

PRODUCT GUIDES

Compare all instruments
and software systems

DEPARTMENTS

Chronological index
2013–2018

WEBINARS

Register Now and
On Demand

Home » MARKETPLACE, Marketplace Archives

Liquid biopsy for differential diagnosis of early stage lung cancer, 5/18

 

May 2018—Integrated Diagnostics announced the e-publication of full results of a large prospective clinical trial validating its Xpresys Lung 2 in Chest, titled “Assessment of plasma proteomics biomarker’s ability to distinguish benign from malignant lung nodules: results of the PANOPTIC (PulmonAry NOdule Plasma proTeomIc Classifier) trial” (Silvestri GA, et al. March 1, 2018. doi:10.1016/j.chest.2018.02.012). The clinical validation represents the performance of the Xpresys Lung 2, a second-generation liquid biopsy for the differential diagnosis of early stage lung cancer. The test combines five standard-of-care clinical factors such as patient age and nodule size in combination with the measurement of two proteins, LG3BP and C163A, into a single risk assessment. The validation study confirmed the high accuracy of the XL2 in identifying benign nodules in patients with a pretest probability of malignancy of 50 percent and less.

Integrated Diagnostics, 206-576-6300

Print Friendly, PDF & Email
Tags:

X